Recently, the identification of disease-specific molecular aberrations has triggered the development of targeted therapies (e.g.: FLT3 inhibitors, IDH1/2 inhibitors), to improve the clinical outcome of AML patients (2, 3). This evidence concerns the gene FLT3 and acute myeloid leukemia.